Wyeth Prevnar Vaccine: First Target Group Is 7 Mil. Infants Under Two
Wyeth-Lederle's Prevnar launch in early March will initially be aimed at the approximately 7 mil. children in the U.S. under two years of age and several high-risk and minority populations.
You may also be interested in...
The wave of new adjuvant-boosted vaccines under development promises to protect new and broader populations against a host of previously elusive pathogens - including pandemic flu. However, until FDA has more experience with these novel combinations, the regulatory hurdles will remain high, speakers warned at the recent Immunotherapeutics & Vaccine Summit in Cambridge, Mass
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011